Evidence map›Paper›PMID 41746050›Full record

ArticleVaccines2026

Development and Validation of a Functional Antibody Assay for Evaluating Protein-Based Pneumococcal Vaccines.

Jiangjiao Li, Kang Li, Youyou Wang, Yang Huang, Xiuwen Sui, Xiao Xu, Huijing Du, Bochao Wei, Ying Yang, Jinming Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jiangjiao LiState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102629, China.ORCID 0009-0005-5936-038X
Kang LiState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102629, China.
Youyou WangState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102629, China.
Yang HuangState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102629, China.
Xiuwen SuiCanSino Biologics Research Center, Tianjin 300457, China.
Xiao XuState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102629, China.
Huijing DuState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102629, China.
Bochao WeiCanSino Biologics Research Center, Tianjin 300457, China.
Ying YangCanSino Biologics Research Center, Tianjin 300457, China.
Jinming ZhangCanSino Biologics Research Center, Tianjin 300457, China.
Liang KongCanSino Biologics Research Center, Tianjin 300457, China.
Tao ZhuCanSino Biologics Research Center, Tianjin 300457, China.ORCID 0000-0003-4197-0065
Bin WangState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102629, China.

Funding

Fund of the State Key Laboratory of Drug Regulatory Science of China 2024SKLDRS0209National Key Research and Development Program of China 2024YFC2310600
6 · The paper itself

Abstract

background

methodsThis study established a robust functional antibody detection method for PspA-based protein vaccines by modifying the conventional multiplex opsonophagocytic killing assay (MOPA), originally designed for polysaccharide-based vaccines. Using polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) typing, a target strain panel was selected and developed to include representative strains from PspA Family 1-Clade 2 and Family 2-Clades 3 and 4. The MOPA protocol was optimized by extending the phagocytic reaction time to enhance sensitivity. Specificity was confirmed through recombinant PspA competitive inhibition assays.

resultsThe assay demonstrated high linearity (R

conclusionsThis study provided a standardized framework to support the development and regulatory assessment of protein-based pneumococcal vaccines.

Indexed as

functional antibodyPneumococcal surface protein Apneumococcal vaccinesStreptococcus pneumoniaevalidation

Identifiers

PMID41746050
PMCPMC12945081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.